BRIEF-Paratek Pharmaceuticals, U.S. Department of defense enter research agreement
Oct 11 Paratek Pharmaceuticals Inc
* Paratek Pharmaceuticals Inc - Paratek, U.S. Department of defense enter research agreement to study omadacycline against biodefense pathogens
* Paratek Pharmaceuticals - co will provide omadacycline and technical expertise to support Usamriid's conduct of pre-clinical pharmacokinetic studies Source text for Eikon: Further company coverage:
Nikkei edges up as dollar-yen steady; Takata files for bankruptcy protection
TOKYO, June 26 Japan's Nikkei share average ticked up on Monday morning as the dollar-yen held steady, while investors' attention fell squarely on Takata Corp after it filed for bankruptcy protection.